… A value of P ≤ 0.05 in an association test and a value of P ≤ 0.10 in a heterogeneity test
were considered to be statistically significant. For each binary outcome, the method with the …

Direct new oral anticoagulants (NOACs) – inhibitors of thrombin or factor Xa – are intended
to be used largely in the treatment of venous thromboembolic disease or the prevention of …

… The OR was matched with its 95% confidence interval (CI) and a significant association
between APL and risk of venous or arterial thrombotic events was concluded at p < 0.01 in the …

… confidence interval [CI], −0.8 to 1.5; P<0.001 for the prespecified noninferiority margin).
The … % of patients assigned to dabigatran and in 6.8% of patients assigned to warfarin (P=0.05). …

Background Dabigatran, which is administered in a fixed dose and does not require
laboratory monitoring, may be suitable for extended treatment of venous thromboembolism. …

Background: Low molecular weight heparins (LMWHs) have become routine thromboprophylaxis
in general surgery. However, their actual clinical effect, its magnitude relative to that of …

Background— Dabigatran and warfarin have been compared for the treatment of acute
venous thromboembolism (VTE) in a previous trial. We undertook this study to extend those …

… , patients with symptomatic nonmassive PE at presentation exhibited a 5.42-fold higher
risk of fatal PE compared with patients with deep-vein thrombosis without symptomatic PE (P<…

… occurred in 20 of 1608 patients (1.2%) receiving semuloparin, as compared with 55 of 1604
(3.4%) receiving placebo (hazard ratio, 0.36; 95% confidence interval [CI], 0.21 to 0.60; P<…

… Dr Mismetti reports receiving research grants from Bayer and fees for board memberships
from Bayer, Bristol-Myers Squibb/Pfizer, and Daiichi Sankyo, for lectures from Bayer, …